Equities
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Draegerwerk AG & Co KGaA is a Germany-based provider of medical and safety technology. The Company operates through two segments: Medical and Safety. The Medical segment develops, produces and markets system solutions, equipment and services for the optimization of processes at the acute point of care, such as emergency care, preoperative care, critical care and prenatal care. The Safety segment develops, produces and markets products, system solutions and services for personal protection, gas detection technology and integrated hazard management for customers from various industries, such as mining, fire departments, police and disaster protection. The Company has production sites in Europe, the Americas, Africa and Asia.

  • Revenue in EUR (TTM)3.35bn
  • Net income in EUR100.48m
  • Incorporated1970
  • Employees16.48k
  • Location
    Draegerwerk AG & Co KGaAMoislinger Allee 53-55LUEBECK 23558GermanyDEU
  • Phone+49 4518820
  • Fax+49 4 518822080
  • Websitehttps://www.draeger.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Safilo Group SpA1.02bn-24.65m484.25m3.83k--1.2816.620.4726-0.0596-0.05962.480.91651.131.804.91267,693.80-2.87-7.06-4.47-11.3057.1652.70-2.55-6.871.101.940.2848---4.832.39-145.51---15.50--
CellaVision AB62.05m12.37m547.44m223.0044.258.2434.358.825.925.9229.6931.810.7571.688.453,106,469.0015.0915.3017.3418.2467.5269.0319.9419.982.2166.290.0688110.185.9413.1710.128.0030.458.45
Advanced Medical Solutions Group plc148.32m18.67m554.43m850.0029.961.9317.693.740.07240.07240.57551.120.44261.755.34148,482.405.576.546.047.0655.5756.7512.5914.824.00--0.036125.851.514.23-22.14-6.7115.6612.32
Stratec SE252.30m12.15m579.32m1.47k47.692.5319.172.300.99910.999120.7518.860.59061.345.11165,771.402.847.073.558.2025.6027.324.819.700.80294.410.382640.81-4.636.88-55.293.30-2.16-7.68
medmix AG497.47m306.70k709.54m2.66k1,678.641.4712.391.430.010.0111.9111.410.46063.656.05183,070.000.06632.060.08462.4932.4136.380.14394.161.232.920.424467.701.991.40-97.41-64.3612.01--
Paul Hartmann AG2.35bn28.42m717.46m10.17k25.120.67135.280.30498.008.00662.57299.401.182.025.72231,438.001.643.872.265.3456.0156.711.392.981.164.870.186542.751.802.12-21.37-18.495.952.71
Revenio Group Oyj96.68m19.01m750.27m216.0039.037.4932.697.760.72050.72053.663.760.70695.507.60447,574.1013.9014.3316.7717.9051.0150.7319.6621.131.7928.490.152155.81-0.412525.80-12.1518.7217.676.30
Synsam AB (publ)526.93m30.49m772.66m3.52k25.153.378.061.472.342.3440.4517.460.72722.0510.941,762,379.004.18--5.85--75.31--5.75--0.50--0.5659--11.90---5.18------
El En SpA692.29m48.24m805.49m2.11k16.662.3213.011.160.60380.60388.674.330.95152.044.05332,511.906.887.4312.8313.5239.1438.837.237.631.20232.140.164--2.7814.88-12.4723.49-13.40--
Draegerwerk AG & Co KGaA3.35bn100.48m907.05m16.48k8.720.61173.610.27095.365.36178.4876.351.112.614.94205,046.003.393.265.034.8743.3244.163.063.051.175.790.166211.3810.785.39271.0533.872.6455.73
Arjo AB (publ)972.49m45.38m1.03bn6.71k24.361.567.601.061.901.9040.7629.720.69114.156.311,632,980.003.213.554.445.5543.4344.014.645.410.69134.140.402443.0110.035.976.9010.15-8.8910.35
Medartis Holding AG216.74m632.83k1.06bn829.001,567.623.7148.054.900.04880.048817.3320.630.62590.6435.27255,737.000.1830.19190.20950.215379.0482.330.29240.35421.591.460.16550.0015.9611.81110.70-31.825.37--
Oxford Nanopore Technologies PLC199.39m-181.57m1.09bn1.24k--1.43--5.46-0.1851-0.18510.20350.74930.2120.83692.73137,050.10-19.30-21.12-21.93-24.6753.3353.90-91.06-81.853.87--0.0608---14.5739.15-69.74--8.92--
GVS SpA424.67m20.54m1.16bn4.39k58.403.3417.742.730.11350.11352.381.990.42011.956.2096,823.302.037.352.5010.8253.9258.744.8412.441.193.870.5709--9.5815.25-43.37-9.9716.08--
Xvivo Perfusion AB56.32m8.80m1.21bn148.00132.656.9284.0721.563.323.3221.1863.590.3221.284.274,018,431.005.031.245.491.3373.9473.1415.624.763.40--0.01520.0043.8826.04398.2948.5721.35--
Biotage AB173.54m20.67m1.30bn669.0061.583.8136.817.493.013.0125.5748.610.52762.017.782,939,169.006.2910.747.3312.7762.1961.3411.9115.771.528.950.06240.1118.9015.37-8.217.9714.051.30
Data as of May 31 2024. Currency figures normalised to Draegerwerk AG & Co KGaA's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.